Daiichi Sankyo shares results for Ezharmia as lymphoma treatment

Betsy Goodfellow | December 11, 2023 | News story | Medical Communications Daiichi Sankyo, Ezharmia, Oncology, lymphoma 

Daiichi Sankyo has announced results from the phase 2 VALENTINE-PTCL01 trial of Ezharmia (valemetostat tosilate), which demonstrated a clinically meaningful and durable response in patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL).

The data has been presented at an oral session at the 2023 American Society of Hematology (ASH23) annual meeting.

The drug had an objective response rate (ORR) of 43.7% in 119 patients with R/R PRCL. There were 17 complete responses and 35 partial responses throughout the trial, with a median duration of response of 11.9 months after a median follow-up of 9.7 months. A median progression-free survival of 5.5 months was seen after a median follow-up of 11.3 months and a median overall survival of 17 months was noted after a median follow-up of 12.3 months.

Advertisement

Steven M Horowitz MD, department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, US, commented: “The high response rates and durability of responses observed with valemetostat in patients with R/R PTCL are very encouraging. Relapse is too frequent in PTCL and there is an acute need for new medicines beyond standard chemotherapy to better control the disease in the relapsed or refractory setting and improve patient outcomes.”

Betsy Goodfellow

Related Content

AAX Biotech and Daiichi Sankyo partner to evaluate antibody therapeutics

AAX Biotech, a Swedish biotechnology company specialising in next-generation antibody therapeutics, has launched a strategic …

Genmab to submit FDA application for lymphoma therapy

Global biotechnology company Genmab plans to submit a supplemental Biologics License Application (sBLA) to the …

Lung xray image

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070

Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …

The Gateway to Local Adoption Series

Latest content